Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives $44.00 Average Price Target from Brokerages

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) have received a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $44.00.

Several analysts have recently commented on the company. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Assembly Biosciences in a research report on Monday, May 4th. Mizuho set a $45.00 price objective on Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Finally, Guggenheim reiterated a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC boosted its position in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 6,823 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 3,312 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after purchasing an additional 248,287 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Assembly Biosciences in the 3rd quarter worth $485,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Assembly Biosciences in the 3rd quarter worth $3,120,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Stock Performance

Shares of ASMB stock opened at $27.48 on Friday. The stock’s fifty day moving average is $26.69 and its 200-day moving average is $28.55. The stock has a market capitalization of $436.66 million, a PE ratio of -249.80 and a beta of 1.07. Assembly Biosciences has a 52 week low of $16.90 and a 52 week high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.11. The company had revenue of $8.21 million for the quarter, compared to analysts’ expectations of $9.27 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%. As a group, analysts forecast that Assembly Biosciences will post 1.9 earnings per share for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.